303 related articles for article (PubMed ID: 35094950)
1. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Kaddu-Mulindwa D; Gödel P; Kutsch N; Heger JM; Scheid C; Borchmann P; Holtick U; Held G; Thurner L; Bewarder M; Rixecker T; Bittenbring JT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e498-e506. PubMed ID: 35094950
[TBL] [Abstract][Full Text] [Related]
2. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
[TBL] [Abstract][Full Text] [Related]
3. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Villa D; Seshadri T; Puig N; Massey C; Tsang R; Keating A; Crump M; Kuruvilla J
Haematologica; 2012 May; 97(5):751-7. PubMed ID: 22180434
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
8. Consolidation therapy with autologous stem cell transplantation after remission of induction chemotherapy prolongs the survival of patients with peripheral T-cell lymphoma.
Fulati W; Ma J; Wu M; Qian W; Chen P; Hu Y; Chen M; Xu Y; Huang Z; Zhang H; Xie Y; Shen L
Front Immunol; 2024; 15():1382189. PubMed ID: 38799461
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
[TBL] [Abstract][Full Text] [Related]
11. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
[TBL] [Abstract][Full Text] [Related]
12. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
13. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma.
Okay M; Büyükaşık Y; Demiroğlu H; Malkan ÜY; Çiftçiler R; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe Oİ; Göker H
Turk J Med Sci; 2019 Aug; 49(4):985-992. PubMed ID: 31293116
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
[TBL] [Abstract][Full Text] [Related]
16. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
17. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
18. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
19. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH
Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]